

ESTEE LAUDER COMPANIES INC
 Form 4
 December 10, 2010

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 LAUDER RONALD S

2. Issuer Name and Ticker or Trading Symbol
 ESTEE LAUDER COMPANIES INC [EL]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
 12/08/2010

___ Director ___X___ 10% Owner
 ___X___ Officer (give title below) ___ Other (specify below)
 Chairman, Clinique Labs, LLC

C/O THE ESTEE LAUDER COMPANIES INC., 767 FIFTH AVENUE

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 ___X___ Form filed by One Reporting Person
 ___ Form filed by More than One Reporting Person

NEW YORK, NY 10153

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
| | | | | (A) or (D) | Price | | |
| Class A Common Stock | 12/08/2010 | | C ⁽¹⁾ | 400,000 | A (3) | 457,553 | D |
| Class A Common Stock | 12/08/2010 | | S | 150,000 ⁽⁴⁾ | D | \$ 77.4809 ^{(4) (5)} | 307,553 D |
| Class A Common Stock | 12/09/2010 | | S | 197,520 ⁽⁴⁾ | D | \$ 78.0499 ^{(4) (6)} | 110,033 D |

Edgar Filing: ESTEE LAUDER COMPANIES INC - Form 4

| | | | | | | | | |
|----------------------------|------------|---|----------------------|---|--|---------|------------------|--|
| Class A Common Stock | 12/09/2010 | S | 2,480 ⁽⁴⁾ | D | \$ 78.4995 <u>(4)</u> <u>(7)</u> | 107,553 | D | |
| Class A Common Stock | | | | | | 3,182 | I ⁽²⁾ | By Decendants of RSL 1966 Trust |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares | |
|---|--|---|---|--------------------------------------|---|--|---|-------------------------------------|---------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | |
| Class B Common Stock | \$ 0 ⁽³⁾ | 12/08/2010 | | C ⁽¹⁾ | 400,000 | <u>(3)</u> | <u>(3)</u> | Class A Common Stock | 400,000 |
| Class B Common Stock | \$ 0 ⁽³⁾ | | | | | <u>(3)</u> | <u>(3)</u> | Class A Common Stock | 3,182 |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| LAUDER RONALD S C/O THE ESTEE LAUDER COMPANIES INC. 767 FIFTH AVENUE NEW YORK, NY 10153 | | X | Chairman, Clinique Labs, LLC | |

Signatures

Ronald S. Lauder, by Spencer G. Smul,
Attorney-in-fact

12/10/2010

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On August 25, 2010, Ronald S. Lauder ("RSL") converted 350,000 shares of Class B Common Stock into an equal number of shares of Class A Common Stock.
 - (2) RSL disclaims beneficial ownership of these shares to the extent he does not have a pecuniary interest in such securities.

There is no exercise or conversion price for the Class B Common Stock. Shares of Class B Common Stock (i) may be converted immediately on a one-for-one basis by the holder into shares of Class A Common Stock and (ii) are automatically converted into Class A
 - (3) Common Stock on a one-for-one basis upon transfer to a person or entity that is not a "Permitted Transferee" (as defined in the Issuer's Restated Certificate of Incorporation) or soon after a record date for a meeting of stockholders where the outstanding Class B Common Stock constitutes less than 10% of the outstanding shares of Common Stock of the Issuer.

The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of
 - (4) sales prices. The price reported represents the weighted average price. RSL undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by such reporting person at each separate price within the range.
 - (5) Sales prices range from \$77.30 to \$78.01 per share, inclusive.
 - (6) Sales prices range from \$77.45 to \$78.44 per share, inclusive.
 - (7) Sales prices range from \$78.45 to \$78.56 per share, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.